soulful sepulcher (Free subscription) | 07/23/2008
ISP ASTRAZENECA PHARMACEUTICALS LP Domain - City WILMINGTON Region DELAWARE Country UNITED STATES Date Time WebPage July 23, 2008 8:07:57 AM soulful sepulcher: The Carlat Blog: Troubles at Mass General:Biederman's million dollar mistake: greed http://bipolarsoupkitchen-stephany.blogspot.com/2008/06/carlat-blog-troubles-at-mass .html
PR News Wire (Free subscription) | 07/23/2008
WILMINGTON, Del., July 23 /PRNewswire-FirstCall/ -- More than a third of the people who contacted AstraZeneca (NYSE: ) to inquire about the company's prescription savings programs learned of the programs from their doctors or pharmacists, according to a year-long survey of more than 12,000 patients. The survey found that 35 percent of the patients who called AstraZeneca's information center regarding...
Contract Pharma Breaking News (Free subscription) | 07/23/2008
Bristol-Myers Squibb and AstraZeneca have submitted an NDA to the FDA and a MAA to the EMEA for Onglyza (saxagliptin) for the treatment of type 2 diabetes. The submissions are based on data from a clinical program conducted in addition to standard therapies, as well as in treatment naïve patients as a monotherapy. The program included studies that evaluated the drug at doses as high as 80 times therapeutic...
Life Science World (Free subscription) | 07/22/2008
[JOB] AstraZeneca, Delaware, Delaware, USA
Life Science World (Free subscription) | 07/22/2008
[JOB] AstraZeneca, Sommerville, NJ, USA
Life Science World (Free subscription) | 07/22/2008
[JOB] AstraZeneca, Delaware, Delaware, USA
Life Science World (Free subscription) | 07/22/2008
[JOB] AstraZeneca, Delaware, Delaware, USA
Life Science World (Free subscription) | 07/22/2008
[JOB] AstraZeneca, Delaware, Delaware, USA
Inbox Robot: Swiss Reinsurance News (Free subscription) | 07/21/2008
LONDON (SHARECAST) - UBS has raised its price target for Autonomy to 1150p from 1050p after the search software specialist announced its results this morning. The ...
PharmaGossip (Free subscription) | 07/17/2008
AZ ethics: Not an oxymoron! AstraZeneca is training staff in a new Code of Conduct that aims to ensure employees at all levels and locations act appropriately. The Code covers a number issues, including interactions with healthcare professionals, conflicts of interest and the ethics of R&D. It goes further than the recently revised EFPIA or PhRMA rules and explicitly spells out dos and don'ts on additional...
soulful sepulcher (Free subscription) | 07/17/2008
Teva gets generic Zyprexa. Teva-Novopharm, known for gaining generic patents of drugs, (as I wrote about earlier regarding AstraZeneca remaining in control of the Seroquel patent until 2012) has a generic version of the antipsychotic that carries a black box warning for diabetes Zyprexa. Eli Lilly has been in hot water for a long time with Zyprexa, and now that there is a generic version of
Fiercebiotech (Free subscription) | 07/16/2008
Infinity Pharmaceuticals' shares fell on the news that it has halted a Phase II trial of IPI-504 for prostate cancer. The company, which partnered with MedImmune/AstraZeneca on the drug, said it has not observed evidence of biologic activity in the trial and has, therefore, concluded that the overall risk-benefit ratio does not justify continuing a signal-finding study as a single agent in this indication....
Medical News Today (Free subscription) | 07/16/2008
Two leading mental health charities, Rethink and MDF The BiPolar Organisation today announced the start of a new partnership with and project sponsored by AstraZeneca. It comprises of experiential research to identify what hinders and helps achieve recovery and aims to help to put recovery at the heart of mental health reform. It will report late 2008.
Mistaken Phil (Free subscription) | 07/15/2008
Time for a quick look at another FTSE100 constituent. And, for once, an interesting one! AstraZeneca (AZN) is a large, diversified pharmaceutical company. The market cap. is about £34 Billion, the yield is about 4% and the PE about 10. AZN markets a bewildering array of drugs, some of which are growing some of which are not. The number of drugs on its books makes it hard to analyse but does lower the...
Seeking Alpha (Free subscription) | 07/14/2008
Aaron F. Barkoff submits: AstraZeneca v. Teva Pharms. USA and Sandoz , No. 05-5333 (D.N.J. 2008) On July 1, the U.S. District Court for the District of New Jersey granted AstraZeneca's (AZN) motion for summary judgment that its patent on quetiapine fumarate, the active ingredient in Seroquel , is not unenforceable for inequitable conduct. The decision disposed of the last remaining issue in the case,...
The last article published by a user on AstraZeneca :
sunilnair | 12/25/2007
AstraZeneca plc (incl. MedImmune Inc.): PharmaVitae Profile Introduction This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool...
